Sunday 15 November 2026
Export BRVE’s income statement to Excel — free account
Braveheart Bio, Inc.
BRVE- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
19.62
0.88
−4.29%
Follow BRVE
Alert me
Braveheart Bio, Inc. (BRVE) news
The news and the share price important stories, numbered as below
Stories the last two months, newest first
More headlines
- Braveheart Bio to Participate in the Jefferies Global Healthcare Conference in London GlobeNewswire
- Where Does Braveheart Bio (BRVE) Value Sit After AHA Data? Simply Wall St.
- Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026 GlobeNewswire
- Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026 GlobeNewswire
- Braveheart Bio to Participate in Stifel Cardiometabolic Forum
- Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
- Braveheart Bio to Participate in Cantor Global Healthcare Conference
- Jefferies starts biopharma firm Braveheart at Buy after IPO
- Braveheart Bio (BRVE) Raised $382.5 Million In Its IPO
- Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Braveheart Bio Announces Pricing of Upsized Initial Public Offering